Business Update

Diagnostic technology company's HIV test remains choice of U.S hospitals

Published in Vaccine Weekly, February 16th, 2005

MedMira Inc. (TSX Venture: MIR, NASDAQ:MMIRF) announced that the results of the 2004 U.S. Centers for Disease Control and Prevention (CDC) HIV Rapid Testing performance evaluation showed that MedMira's Reveal Rapid HIV-1 Antibody Test (Reveal) remains the test of choice in U.S. hospitals for the second consecutive year.

The 2004 CDC study asked participants to evaluate a panel of HIV-positive and negative donor specimens, that were provided by the CDC, using the rapid HIV test utilized at their facility. A total of 384 participating testing sites took part in the study. The study results indicated that the accuracy of the Reveal test with HIV-positive specimens was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry